Page 471 - Binder2

Let’s trace the arc:

• We started with patients whose bodies rejected
life-changing therapies—not because the
molecules were wrong, but because the delivery, the
duration, the design was never built for coexistence.
• We exposed an industry that normalized
switching, hid ADA rates, and optimized for
escalation.
• We followed the innovators who said: “Enough.”
Startups who encoded immune tolerance. Scientists
who used plants instead of tanks. Regulators who
began to rethink what “effective” really means.
• We outlined how policy, mindset, and capital
must evolve—not to reward speed or spectacle, but
endurance.
• And we heard the call—from patients, from
researchers, from anyone who believes drugs
should work longer than the next billing cycle.

This is the revolution. It’s not coming. It’s already here.

We Don’t Need New Molecules. We Need New Rules.

The great myth of modern biologics is that the solution lies
in the next compound, the next sequence, the next patent.
But the problem was never a shortage of molecules. It was
a shortage of imagination.

What we need now is not just new science, but new
values. A new set of expectations about what biologics can
and should do. A belief that the immune system isn’t
something to trick—but something to teach.

469